Z Squared Inc. quarterly report, Q2 FY2024

SEC Filing Summary: Coeptis Therapeutics Holdings, Inc. (COEP)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2024. Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company focused on developing cell therapy technologies for cancer and other diseases. The company operates as a holding company with subsidiaries including Coeptis Therapeutics, Inc., SNAP Biosciences Inc., and GEAR Therapeutics Inc. It is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Metric Three Months Ended June 30, 2024 Six Months Ended June 30, 2024 As of June 30, 2024
Revenue $0 $0 N/A
Net Loss $(3,035,345) $(6,036,733) N/A
Loss Per Share (Basic & Diluted) $(0.08) $(0.17) N/A
Cash and Cash Equivalents N/A N/A $1,555,075
Total Assets N/A N/A $4,198,420
Total Liabilities N/A N/A $4,508,480
Stockholders' Equity (Deficit) N/A N/A $(310,060)
Notes Payable (Current) N/A N/A $1,553,929
Notes Payable (Long-Term) N/A N/A $150,000

Note: The company reported no revenue for the periods presented. Operating expenses totaled $2,828,102 for the quarter and $5,750,485 for the six-month period.

Material Changes vs. Prior Period

  • Operating Expenses: Decreased significantly from $3,684,984 in Q2 2023 to $2,828,102 in Q2 2024, primarily due to lower professional services expenses related to equity transactions.
  • Net Loss: Improved slightly on a quarterly basis (from $(3.2M) to $(3.0M)) and significantly on a six-month basis (from $(11.2M) to $(6.0M)).
  • Derivative Liability: The fair value of warrant liabilities increased by $114,375 during the six months ended June 30, 2024, resulting in a non-cash loss.
  • Capital Structure: The company completed an initial closing of a Series A Preferred Stock offering in June 2024, raising $4.3 million. Additionally, $7.6 million in subscription receivables is recorded as a contra-equity account.
  • Debt: Current notes payable increased from $975,000 at year-end 2023 to $1,553,929, reflecting new borrowings and extensions of maturity dates.

Outlook, Risks, and Management Commentary

  • Going Concern: The filing explicitly states that the company's accumulated deficit of $93.4 million and net losses raise substantial doubt about its ability to continue as a going concern. Management plans to raise additional capital through equity or debt sales to sustain operations.
  • Revenue Outlook: Management does not expect to generate significant revenue for at least the next two years while drug development continues.
  • Strategic Focus: The company is focusing on co-development partnerships, specifically with Vy-Gen Bio (CD38-GEAR-NK and CD38-Diagnostic) and Deverra Therapeutics (NK cell therapy platform). Previous commercial products (anti-hypertension) have been abandoned.
  • Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to self-identified material weaknesses in internal accounting personnel and financial statement close processes.
  • Subsequent Events: A second closing of the Series A offering occurred on July 31, 2024, raising an additional $1.3 million. On August 12, 2024, $5.7 million of subscription receivables were satisfied via issuance of common stock in two privately held companies.

Investor Verification Checklist

  • Liquidity Runway: Verify the sufficiency of the $1.55 million cash balance against the $1.55 million in current notes payable due within 12 months.
  • Subscription Receivables: Confirm the collectability of the $7.6 million subscription receivable balance, which is currently recorded as a contra-equity item.
  • Series A Offering Terms: Review the specific conversion terms, beneficial ownership limitations, and liquidation preferences of the newly issued Series A Preferred Stock.
  • Internal Control Remediation: Assess the timeline and plan for remedying the material weaknesses in internal controls over financial reporting.
  • Debt Maturities: Monitor the repayment or extension status of the $1.55 million in current notes payable, several of which have been extended multiple times.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.